Get the Stockscreener App
689.45
2.34%
-16.55
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Mckesson Corporation stock is traded at $689.45, with a volume of 1.22M.
It is down -2.34% in the last 24 hours and down -2.82% over the past month.
McKesson Corp is one of three leading pharmaceutical wholesalers in the US engaged in sourcing and distributing branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with Cencora and Cardinal Health, the three account for over 90% of the US pharmaceutical wholesale industry. Outside the US market, McKesson engages in pharmaceutical wholesale and distribution in Canada. Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
See More
Previous Close:
$706.00
Open:
$705.63
24h Volume:
1.22M
Relative Volume:
1.63
Market Cap:
$85.76B
Revenue:
$377.60B
Net Income/Loss:
$3.35B
P/E Ratio:
27.49
EPS:
25.08
Net Cash Flow:
$5.67B
1W Performance:
+2.44%
1M Performance:
-2.82%
6M Performance:
+15.35%
1Y Performance:
+22.92%
1-Day Range:
$684.71
$709.50
1-Week Range:
$667.50
$709.50
52-Week Range:
$464.42
$737.89
Mckesson Corporation Stock (MCK) Company Profile
Name
Mckesson Corporation
Sector
Industry
Phone
972-446-4800
Address
6555 STATE HIGHWAY 161, IRVING, TX
Compare MCK with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MCK
Mckesson Corporation
|
689.45 | 83.49B | 377.60B | 3.35B | 5.67B | 25.08 |
|
COR
Cencora Inc
|
292.60 | 56.29B | 316.65B | 1.91B | 1.14B | 9.72 |
|
CAH
Cardinal Health Inc
|
148.10 | 35.75B | 222.58B | 1.57B | 1.85B | 6.45 |
|
HSIC
Henry Schein Inc
|
69.60 | 8.15B | 12.50B | 314.00M | 421.00M | 2.44 |
|
AHG
Akso Health Group Adr
|
1.77 | 701.93M | 2.22M | -5.63M | -1.68M | -0.24 |
Mckesson Corporation Stock (MCK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-04-24 | Resumed | Mizuho | Neutral |
| Nov-07-24 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Sep-24-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Sep-05-24 | Reiterated | Leerink Partners | Outperform |
| Aug-08-24 | Reiterated | Mizuho | Neutral |
| Feb-26-24 | Initiated | Leerink Partners | Outperform |
| Jan-03-24 | Initiated | Barclays | Overweight |
| Dec-14-23 | Initiated | Wells Fargo | Equal Weight |
| Mar-31-23 | Initiated | Citigroup | Buy |
| Aug-22-22 | Resumed | Morgan Stanley | Overweight |
| Jul-06-22 | Downgrade | Argus | Buy → Hold |
| Jun-07-22 | Upgrade | Deutsche Bank | Hold → Buy |
| Apr-01-22 | Resumed | Credit Suisse | Outperform |
| Feb-04-22 | Downgrade | Deutsche Bank | Buy → Hold |
| Jan-07-22 | Upgrade | Credit Suisse | Neutral → Outperform |
| Nov-02-21 | Reiterated | Barclays | Overweight |
| Nov-02-21 | Reiterated | BofA Securities | Buy |
| Nov-02-21 | Reiterated | Evercore ISI | Outperform |
| Nov-02-21 | Reiterated | Jefferies | Buy |
| Mar-30-21 | Upgrade | Argus | Hold → Buy |
| Nov-02-20 | Upgrade | Barclays | Equal Weight → Overweight |
| Aug-04-20 | Upgrade | Deutsche Bank | Hold → Buy |
| May-22-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| May-15-20 | Upgrade | UBS | Neutral → Buy |
| Apr-23-20 | Resumed | Credit Suisse | Neutral |
| Mar-18-20 | Upgrade | Goldman | Neutral → Buy |
| Mar-13-20 | Upgrade | Guggenheim | Neutral → Buy |
| Feb-07-20 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jan-10-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-12-19 | Initiated | Deutsche Bank | Hold |
| Aug-05-19 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jul-22-19 | Initiated | Guggenheim | Neutral |
| Jan-17-19 | Initiated | UBS | Neutral |
| Oct-26-18 | Reiterated | Barclays | Equal Weight |
| Jul-20-18 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-29-18 | Reiterated | Leerink Partners | Mkt Perform |
| Mar-08-18 | Initiated | Barclays | Equal Weight |
| Feb-27-18 | Resumed | BofA/Merrill | Buy |
| Feb-02-18 | Reiterated | Mizuho | Neutral |
| Jan-24-18 | Upgrade | Jefferies | Hold → Buy |
View All
Mckesson Corporation Stock (MCK) Latest News
McKesson Corp. stock outperforms competitors on strong trading day - MarketWatch
Stock Analysis | McKesson OutlookNavigating a Neutral Technical Landscape Amid Mixed Fundamentals - AInvest
McKesson Navigates Insider Sales and Institutional Confidence Amid $340M Volume, 282nd in Market - AInvest
McKesson price target raised to $772 from $766 at Wells Fargo - MSN
McKesson CEO Tyler sells $8.08 million in stock - Investing.com
McKesson Defends Payments as Rite Aid Seeks Bankruptcy Clawback - Bloomberg Law News
Now Is the Time to Reframe Your Health System Infusion Strategy – Starting with a Deliberate Design and the Right Partnerships - McKesson
How McKesson Corporation stock performs during market volatilityJuly 2025 Gainers & Consistent Income Trade Recommendations - thegnnews.com
Why McKesson Corporation stock attracts strong analyst attentionWeekly Stock Recap & Weekly High Potential Stock Alerts - beatles.ru
Chart Analysts Warn of Resistance Near McKesson Corporation Price2025 Top Gainers & Safe Capital Growth Trade Ideas - newsyoung.net
We Like The Quality Of McKesson's (NYSE:MCK) Earnings - 富途牛牛
Synergy CHC Corp Reports Second Quarter 2025 Financial Results and its Tenth Consecutive Quarter of Profitability - GlobeNewswire Inc.
Can McKesson’s (MCK) Lower Earnings Shift Its Capital Allocation Priorities? - simplywall.st
McKesson Corporation (MCK) is Attracting Investor Attention: Here is What You Should Know - MSN
Wells Fargo Maintains McKesson(MCK.US) With Hold Rating, Raises Target Price to $772 - 富途牛牛
Pharmacy Profiles to provide credential verification services for McKesson's Health Mart pharmacies - Drug Store News
Saudi Arabia Teleradiology Market Trends and Company Analysis Report 2025-2033 Featuring FUJIFILM, Koninklijke Philips, General Electric, Oracle, Siemens, GE, McKesson - Yahoo Finance
Wells Fargo Maintains McKesson (MCK) with Raised Price Target to $772 | MCK Stock News - GuruFocus
Wells Fargo Adjusts Price Target on McKesson to $772 From $766, Maintains Equalweight Rating - MarketScreener
The Top 5 Analyst Questions From McKesson’s Q2 Earnings Call - Yahoo Finance
Zacks Industry Outlook Highlights McKesson, Cardinal Health, West Pharmaceutical Services and The Cooper Companies - The Globe and Mail
J.P. Morgan Keeps Their Buy Rating on McKesson (MCK) - The Globe and Mail
McKesson Corp's shares drop below 200-day moving average, trading at $637.00 per share. - AInvest
How McKesson’s (MCK) Earnings Beat, Dividend Hike, and Spin-Off Plans Have Changed Its Investment Story - simplywall.st
Published on: 2025-08-09 00:46:56 - Newser
Published on: 2025-08-08 22:45:07 - Newser
McKesson Climbs 0.80% Despite 99th-Ranked Trading Volume as Institutional Confidence and Dividend Hike Fuel Long-Term Optimism - AInvest
Deutsche Bank Reaffirms Their Buy Rating on McKesson (MCK) - The Globe and Mail
Mizuho Securities Sticks to Their Hold Rating for McKesson (MCK) - The Globe and Mail
Here's Why McKesson (MCK) is a Strong Value Stock - Yahoo Finance
Pharmaceutical Packaging Market Trends and Company Analysis - GlobeNewswire
Pharmaceutical Packaging Market Trends and Company Analysis Report 2025-2033 Featuring Amcor, 3M, Schott, WestRock, Berry Global, McKesson, AptarGroup, Klockner Pentaplast, CCL, FlexiTuff - Yahoo Finance
Citi Sticks to Its Buy Rating for McKesson (MCK) - The Globe and Mail
McKesson’s Strong Long-Term Growth Potential Justifies Buy Rating Despite Limited Immediate Upside - TipRanks
McKesson First Quarter 2026 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Candlestick signals on McKesson Corporation stock todayBreakout Watcher with Entry and Exit Alerts - Newser
McKesson’s Earnings Call Highlights Strong Growth and Strategic Moves - TipRanks
McKesson Corp. stock underperforms Thursday when compared to competitors - MSN
Relative Strength Alert For McKesson - Nasdaq
Deutsche Bank Adjusts Price Target on McKesson to $775 From $740, Maintains Buy Rating - MarketScreener
McKesson Corporation (NYSE:MCK) Q1 2026 Earnings Call Transcript - Insider Monkey
MCK Stock Down Despite Q1 Earnings Beat & Raised '26 EPS View - Yahoo Finance
McKesson Corp. Exceeds Expectations with Strong Q1 EarningsNews and Statistics - IndexBox
McKesson Increases Profit Forecast Due to Specialty Medicines DemandNews and Statistics - IndexBox
McKesson Achieves 23.4% Revenue Growth in Q2 CY2025News and Statistics - IndexBox
McKesson: Fiscal Q1 Earnings Snapshot - New Haven Register
Earnings call transcript: McKesson’s Q1 2026 results exceed forecasts, stock dips - Investing.com Australia
McKesson Well-Positioned to Benefit from GLP-1s and Increasing Presence in Specialty - Morningstar
McKesson Lifts Forecast As Specialty Medicine Demand Grows - Finimize
McKesson Corporation Reports Strong Q1 2026 Results - TipRanks
Decoding McKesson Corp (MCK): A Strategic SWOT Insight - GuruFocus
Mckesson Corporation Stock (MCK) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.51%
2.04%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):